Thomas Pisano - Nu Skin Independent Director
| NUS Stock | USD 7.55 0.33 4.57% |
Director
Mr. Thomas R. Pisano is an Independent Director of Nu Skin Enterprises, Inc since 2008.
| Age | 75 |
| Tenure | 16 years |
| Professional Marks | MBA |
| Address | 75 West Center Street, Provo, UT, United States, 84601 |
| Phone | 801 345 1000 |
| Web | https://www.nuskin.com |
Nu Skin Management Efficiency
The company has Return on Asset of 0.0555 % which means that on every $100 spent on assets, it made $0.0555 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.135) %, meaning that it generated no profit with money invested by stockholders. Nu Skin's management efficiency ratios could be used to measure how well Nu Skin manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to 0.01 in 2024. Return On Capital Employed is likely to drop to 0.03 in 2024. At this time, Nu Skin's Non Currrent Assets Other are comparatively stable compared to the past year. Intangibles To Total Assets is likely to gain to 0.22 in 2024, whereas Non Current Assets Total are likely to drop slightly above 607.3 M in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Sherilyn McCoy | Kimberly Clark | 62 | |
| Allan Mackay | The Clorox | 65 | |
| Robert Shearer | Church Dwight | 69 | |
| Adrian Hennah | Unilever PLC ADR | 63 | |
| Russell Weiner | The Clorox | 52 | |
| Esther Lee | The Clorox | 62 | |
| Bradley Irwin | Church Dwight | 62 | |
| John Rishton | Unilever PLC ADR | 63 | |
| LAURIE YOLER | Church Dwight | 56 | |
| Amy Banse | The Clorox | 61 | |
| Ian Read | Kimberly Clark | 66 | |
| Martina HundMejean | Colgate Palmolive | 60 | |
| Lisa Edwards | Colgate Palmolive | 53 | |
| Robert Decherd | Kimberly Clark | 69 | |
| Janet Vergis | Church Dwight | 57 | |
| Abelardo Bru | Kimberly Clark | 70 | |
| Arthur Winkleblack | Church Dwight | 63 | |
| Spencer Fleischer | The Clorox | 67 | |
| Stephen Sadove | Colgate Palmolive | 69 | |
| Mae Jemison | Kimberly Clark | 64 | |
| Jessica Warren | Honest Company | 42 | |
Management Performance
| Return On Equity | -0.13 | ||||
| Return On Asset | 0.0555 |
Nu Skin Enterprises Leadership Team
Elected by the shareholders, the Nu Skin's board of directors comprises two types of representatives: Nu Skin inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NUS. The board's role is to monitor Nu Skin's management team and ensure that shareholders' interests are well served. Nu Skin's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nu Skin's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Scott Pond, Director - Investor Relations | ||
| Ritch Wood, CFO, Principal Accounting Officer and VP | ||
| Chayce Clark, Executive Vice President General Counsel | ||
| Joseph Chang, Executive Vice President - Product Development, Chief Scientific Officer | ||
| Ruth Todd, Senior Officer | ||
| Emma Battle, Director | ||
| Thomas Pisano, Independent Director | ||
| Mark Adams, Chief Officer | ||
| Zheqing Shen, Independent Director | ||
| James Thomas, Chief Accounting Officer | ||
| Mang Tang, Strategic Advisor | ||
| Joe Sueper, Senior CTO | ||
| Mark Lawrence, Chief Financial Officer, Executive Vice President | ||
| Sandra Tillotson, Founder | ||
| D Dorny, Executive Vice President, General Counsel, Secretary | ||
| Steve Hatchett, Executive Officer | ||
| Daniel Campbell, Lead Independent Director | ||
| Edwina Woodbury, Independent Director | ||
| Laura Nathanson, Independent Director | ||
| Steven Lund, Executive Chairman of the Board | ||
| Matthew Dorny, VP, General Counsel and Secretary | ||
| Connie Tang, Executive Vice President Chief Global Growth & customer Experience Officer | ||
| Justin Keisel, President Americas | ||
| Blake Roney, Founder | ||
| Steven JD, CoFounder Board | ||
| Andrew Lipman, Independent Director | ||
| Greg Belliston, Assistant Secretary | ||
| Ryan Napierski, President, Chief Executive Officer, Director |
NUS Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nu Skin a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.13 | ||||
| Return On Asset | 0.0555 | ||||
| Profit Margin | (0.06) % | ||||
| Operating Margin | 0.04 % | ||||
| Current Valuation | 622.91 M | ||||
| Shares Outstanding | 49.71 M | ||||
| Shares Owned By Insiders | 2.29 % | ||||
| Shares Owned By Institutions | 81.10 % | ||||
| Number Of Shares Shorted | 1.56 M | ||||
| Price To Earning | 10.70 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for NUS Stock Analysis
When running Nu Skin's price analysis, check to measure Nu Skin's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nu Skin is operating at the current time. Most of Nu Skin's value examination focuses on studying past and present price action to predict the probability of Nu Skin's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nu Skin's price. Additionally, you may evaluate how the addition of Nu Skin to your portfolios can decrease your overall portfolio volatility.